SCHD Did It Again With Healthcare: Why This Fund Keeps Beating The Market

SCHD has outperformed the S&P 500 in 2026 by using a countercyclical sector mix during the Tech and semiconductor correction, aided by its annual reconstitution/rebalance process. The prior March 2024 Broadcom removal—initially viewed as a risk—functioned as part of the same mechanism that later improved performance versus the names that corrected. In the March 2026 rebalance, the fund rotated into Health Care, which now sits at the top of the portfolio.

Analysis

SCHD is behaving less like a static income sleeve and more like a rules-based factor rotation engine. The second-order effect is that any selloff concentrated in high-duration growth automatically improves its relative mix, while its periodic reshuffles create forced demand for defensives and forced supply of the names that just lost index support. That makes the fund a mechanical beneficiary of dispersion, not a pure bet on dividends.

The key losers are the names and sectors that rely on momentum-driven ownership, especially semis and other crowded tech exposures that can face incremental selling after a rebalance. Even high-quality franchises can trade with a weaker technical overhang if they are exiting or being downweighted in dividend-oriented products, while Health Care gets a free flow tailwind from model portfolios and ETF replication. The spillover matters more for relative valuation than absolute fundamentals: this is about who gets marginal capital, not whose earnings changed.

Near term, the trade works as long as tech breadth stays choppy and rates do not fall hard enough to re-ignite a broad multiple expansion in long-duration growth. Over 1-3 months, any stabilization in semis or a broad market rally would likely reverse part of the relative outperformance; over 6-18 months, SCHD should continue to behave as a lower-volatility equity sleeve unless leadership becomes much more concentrated in high-growth sectors. The thesis is falsified if XLK/SOX Q reclaim leadership on improving earnings revisions, because then the fund's defensive tilt becomes a drag rather than a benefit.

Contrarian view: the market may be underestimating how persistent these reconstitution flows are, but it may also be overpaying for a one-off technical edge. The right way to express the view is relative value, not outright equity beta, because the source of alpha is structural flow, not a durable fundamental improvement in the underlying holdings.

Key Decisions for Investors

• Long SCHD / short QQQ as a 1-3 month relative-value pair; use on any tech bounce that fades, targeting continued dispersion compression while preserving market-neutral beta.
• Long XLV / short SOXX for a 1-3 month sector pair if Health Care remains the primary reconstitution beneficiary and semis stay out of favor; cut if SOXX breadth reclaims leadership on earnings revisions.
• Add SCHD on pullbacks as a defensive equity sleeve rather than chasing after outperformance; the setup is best when Nasdaq volatility is still elevated and breadth remains narrow.
• If already overweight AVGO or other mega-cap tech, hedge via a partial short QQQ or XLK overlay into the next rebalance window; the risk is technical underownership, not business deterioration.
• Set an alert for a sustained tech leadership reversal: if XLK and SOXX outperform for several weeks on improving guidance, reduce SCHD-relative longs because the countercyclical flow advantage should fade.